奈达铂腹腔灌注化疗在恶性腹腔积液中的临床疗效观察

CLINICAL CURATIVE EFFCET OF NEDAPLATIN INTRAPERITONEAL CHEMOTHERAPY IN MALIGNANT ASCITES

目的探究恶性腹腔积液分别采取抗肿瘤药物奈达铂与顺铂腹腔灌洗化疗的临床疗效及安全性差异,并为该病临床策略的制定提供数据支持。方法选取该院2010年3月—2013年10月收治的78例恶性腹腔积液患者,利用随机数字表法进行分组,分别设为观察组和对照组,每组各39例。其中观察组开展奈达铂腹腔灌注化疗,对照组开展顺铂腹腔灌注化疗。记录二组患者在治疗期间不良反应发生情况及腹腔积液控制水平。结果二组在腹腔积液消退方面差异无统计学意义(P>0.05)。观察组胃肠道反应发生率低于对照组(P<0.05)。二组在肾功能损伤、骨髓移植及肝功能损伤方面差异无统计学意义(P>0.05)。结论奈达铂与顺铂灌注化疗方案在控制恶性腹腔积液腹方面效果相当,且安全性可,值得在临床上进行推广应用。

Objective To explore the clinical efficacy and safety of malignant celiac effusion which were treated by the antitumor drug nedaplatin and cisplatin intraperitoncal hyperthermic perfusion chemotherapy respectively, and then to provide data for making clinical strategy of this disease. Methods A tatal of 78 cases of malignant peritoneal effusion were collected in author＇s hospital from March 2010 to October 2013. All patients were randomly divided into research group and control group respectively, 39 cases in each group. The research group was given nedaplatin intraperitoneal hypcrthermic perfusion treatment, and the control group was given cisplatin intraperitoneal chemotherapy. The occurrences of adverse reactions and ascites control level in chemotherapy period of the two groups were recorded. Results The scites extinc- tion efficiency in the research group was more higher than that in the control group （P〈0.05）. The gag trointestinal reaction rate in the research group was lower than that in the control group （P〈0.05）. There were no statistical significance in damage, kidney function in bone marrow transplantation and liver function injury （P〉0.05） between the two groups. Conclusion Nedaplatin and cisplatin.chemotherapy scheme is quite effective in controlling malignant ascites and abdominal, security, and is worthy of being popularized in clinic.